Jubilant Life Sciences shares jumped nearly 6 per cent on Monday after it received final approval from the US health regulator for generic Levetiracetam injection, used for treatment of epilepsy, in the American market.
At 10 am, Jubilant Life Sciences scrip was trading 4.66 per cent up at Rs 369.40. The scrip opened at Rs 366.25 and has touched a high and low of Rs 374 and Rs 366.25, respectively, in trade so far. The scrip settled 4.08 per cent up at Rs 367.35.
The BSE group ‘A’ stock of face value Rs 1 has touched a 52 week high of Rs 455.00 on 07-Dec-2015 and a 52 week low of Rs. 163.35 on 29-Jun-2015.
Last one week high and low of the scrip stood at Rs 368.50 and Rs 338.20 respectively. The current market cap of the company is Rs 5893.40 crore.
The promoters holding in the company stood at 54.02 per cent while Institutions and Non-Institutions held 27.56 per cent and 18.41 per cent respectively.
The company has received abbreviated new drug application (ANDA) final approval for Levetiracetam injection USP, 500 mg/5 mL (100 mg/mL) from the United States Food and Drug Administration (USFDA), the company said in a BSE filing.
The company’s product is the generic version of UCB’s Keppra injection in the same strength, it added.
“As on March 31, 2016, Jubilant Life Sciences had a total of 739 filings for formulations, of which 517 have been approved in various regions globally. This includes 72 ANDAs filed in the US, of which 44 have been approved and 46 Dossier filings in Europe,” the company said.